We present the preliminary findings on the ability of our novel whole-body MRI using Dual-Echo T2-weighted acquisition for Enhanced Conspicuity of Tumors (WBMRI-DETECT) for detection and longitudinal assessment of therapy response in multiple myeloma (MM). Data from 4 MM patients undergoing induction therapy at 4 timepoints in an ongoing prospective research study are presented. Our results show that WBMRI-DETECT provides higher SNR, improved lesion conspicuity with shorter scan times compared to WBMRI-STIR and WBMRI-DWIBS, and minimal geometric distortions compared to WBMRI-DWIBS. In addition, quantitative FF measurements from WBMRI can serve as a prognostic imaging biomarker for the treatment response assessment.
This abstract and the presentation materials are available to members only; a login is required.